V. Vladimirov

发表

Excesive Scar Formation After Surgical Operations And Injuries: Expirience of Early Diagnosis and Prophyilaxis

O. Vladimirova, V. Vladimirov, K. Amlaev, 2018, e-Journal of Cardiovascular Medicine.

Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study

A. M. Degtyarev, R. Zukov, A. Vasilevskaya, 2022, Journal of Modern Oncology.

A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.

B. Leyland-Jones, E. Vercammen, I. Bondarenko, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia

E. Imyanitov, R. Zukov, A. Iyevleva, 2021 .

A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.

S. Barni, L. Hart, J. Bendell, 2013 .

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study

E. Tokunaga, I. Bondarenko, O. Lipatov, 2022, BioDrugs.

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.

T. H. Klotz, S. Culine, J. Hainsworth, 2022, The Lancet. Oncology.

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Chris Twelves, Fatima Cardoso, T. Delozier, 2011, The Lancet.

Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens

Yoon-Koo Kang, L. Wyrwicz, Y. Chao, 2019, Annals of Oncology.

Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia

L. Bolotina, V. Gorbunova, E. Ovchinnikova, 2019, Journal of Modern Oncology.

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

R. Govindan, K. O'Byrne, P. Postmus, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer

J. Crown, M. Clemens, O. Gladkov, 2014, Breast Cancer Research and Treatment.

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy

S. Barni, L. Hart, J. Bendell, 2016, International journal of cancer.

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

P. Ascierto, R. Plummer, E. Felip, 2022, Cancer Chemotherapy and Pharmacology.

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

Xidong Jin, Chiun-Sheng Huang, T. Hickish, 2022, Breast Cancer Research and Treatment.

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)

Y. Hotko, K. Syrigos, M. Gumus, 2021, BioDrugs.

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407.

A. Tafreshi, Ying Cheng, B. Halmos, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

N. Reinmuth, I. Bondarenko, K. Syrigos, 2019, BioDrugs.

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study

E. Tokunaga, I. Bondarenko, O. Lipatov, 2022, BioDrugs.

[Influence of connective tissue differentiation on scar tissue formation in children].

S. Minaev, A. Grigorova, O. Vladimirova, 2021, Khirurgiia.

97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407

A. Tafreshi, Ying Cheng, B. Halmos, 2021 .

Abstract S5-07: A randomized, open-label, multicenter, phase 3 study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy

B. Leyland-Jones, K. Lakshmaiah, E. Vercammen, 2015 .

Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407

A. Tafreshi, Ying Cheng, B. Halmos, 2019, Annals of Oncology.

The experience of application of antiscar combined agent with boswellic and hyaluronic acids and cepalin in patients with scars at early stages of their development

O. Vladimirova, V. Vladimirov, P. Lavreshin, 2019, Ambulatory surgery: hospital-replacing technologies.

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer

B. Cho, R. Hauke, I. Lugowska, 2023, ESMO open.

Predictive multigenic scale. Analysis of own results in metastatic breast cancer

E. Imyanitov, S. Aleksakhina, A. Vorontsov, 2023, Tumors of female reproductive system.

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

R. Govindan, K. O'Byrne, P. Postmus, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.